Therapeutic gene modulation

Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19

Thursday, April 2, 2020 - 12:00pm

As part of the original collaboration to advance investigational RNAi therapeutics to treat disease caused by coronavirus infection, Alnylam has designed and synthesized over 350 siRNAs targeting highly conserved regions of the SARS-CoV-2 genome.

Key Points: 
  • As part of the original collaboration to advance investigational RNAi therapeutics to treat disease caused by coronavirus infection, Alnylam has designed and synthesized over 350 siRNAs targeting highly conserved regions of the SARS-CoV-2 genome.
  • Upon DC selection, Vir will lead development efforts working closely with Alnylam to generate the data required to enable the potential for rapid commencement of clinical studies.
  • The biopharmaceutical industry needs to advance its full armamentarium of potential treatment approaches and strategies to address the COVID-19 pandemic.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.

DGAP-News: Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals

Monday, March 23, 2020 - 8:01am

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

Key Points: 
  • Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
  • The antisense oligonucleotide candidates targeting the ANGPTL gene family for the treatment of cardiovascular and metabolic diseases were previously generated by Secarna and Lipigon under a target validation and drug discovery collaboration.
  • Going forward, Lipigon will fund and continue the development of the acquired assets and Secarna receives payments customary for such a transaction.
  • Inhibiting the ANGPTL gene family members ANGPTL3 and ANGPTL4 with Secarna's LNAplusTM based antisense oligonucleotides has shown to positively affect plasma lipid levels.

 Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

Wednesday, March 4, 2020 - 12:00pm

The collaboration will focus on development of siRNAs that Alnylam recently identified that target highly conserved regions of coronavirus RNAs.

Key Points: 
  • The collaboration will focus on development of siRNAs that Alnylam recently identified that target highly conserved regions of coronavirus RNAs.
  • Alternatively, Alnylam may elect to earn development and commercialization milestones and royalties on net sales of products resulting from the collaboration in amounts agreed upon for the coronavirus program.
  • RNAi is a powerful, natural cellular mechanism that can be harnessed to develop a broad range of innovative medicines, including anti-viral therapies.
  • As the leader in RNAi therapeutics, we at Alnylam are committed to doing our part in joining other biopharmaceutical companies, like Vir, to address this emerging outbreak.

Alnylam Announces Changes to its Board of Directors

Thursday, February 27, 2020 - 9:00pm

In addition, Alnylam announces today the retirement of Dr. Paul Schimmel from the Board effective upon the conclusion of his current term at the Annual Meeting of Alnylam stockholders in 2020.

Key Points: 
  • In addition, Alnylam announces today the retirement of Dr. Paul Schimmel from the Board effective upon the conclusion of his current term at the Annual Meeting of Alnylam stockholders in 2020.
  • Schimmel co-founded Alnylam where he served on the Board of Directors and Scientific Advisory Board since the Companys founding in 2002.
  • Following his retirement from the Board of Directors, Dr. Schimmel will continue to serve on the Companys Scientific Advisory Board.
  • We are honored to welcome Olivier to our Board of Directors at this exciting point in Alnylams history.

Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

Thursday, February 27, 2020 - 1:33am

Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D.

Key Points: 
  • Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D.
  • William Goolsbee, non-executive director of Antisense Therapeutics, said, It is great news that Dr. Price has agreed to join our team.
  • The addition of Dr. Price as a Consultant Medical Director is an exciting advance for the Company on many fronts.
  • About Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets.

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Tuesday, February 25, 2020 - 12:00pm

A replay will be available on the Alnylam website within 48 hours after each event.

Key Points: 
  • A replay will be available on the Alnylam website within 48 hours after each event.
  • Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.
  • For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn .

Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference

Thursday, February 20, 2020 - 1:00pm

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020 at 9:30 am ET at the Lotte New York Palace Hotel in New York City.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020 at 9:30 am ET at the Lotte New York Palace Hotel in New York City.
  • A live audio webcast of the presentation will be available on the Investors section of the Companys website at www.alnylam.com/events .
  • A replay will be available on the Alnylam website within 48 hours after the event.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.

Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast

Tuesday, February 18, 2020 - 12:00pm

Akcea Therapeutics, Inc.,a majority-owned affiliate ofIonis Pharmaceuticals, Inc.(NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.

Key Points: 
  • Akcea Therapeutics, Inc.,a majority-owned affiliate ofIonis Pharmaceuticals, Inc.(NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.
  • All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis proprietary antisense technology.
  • In this press release, unless the context requires otherwise, Ionis, Akcea, Company, Companies, we, our, and us refers toIonis Pharmaceuticalsand/orAkcea Therapeutics.
  • Ionis Pharmaceuticals is a trademark ofIonis Pharmaceuticals, Inc., Akcea Therapeutics, TEGSEDIand WAYLIVRAare trademarks ofAkcea Therapeutics, Inc.

Shareholder Alert: Robbins LLP Reminds Investors Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders

Monday, February 10, 2020 - 7:09pm

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 6, 2017 and August 19, 2019.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 6, 2017 and August 19, 2019.
  • Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine for the treatment of rare diseases.
  • Sarepta's products pipeline includes its drug golodirsen for the treatment of duchenne muscular dystrophy ("DMD").
  • According to the complaint, in September 2017, Sarepta announced positive results from its first-in-human study for the safety, tolerability, pharmacokinetics, and efficacy of its drug golodirsen.

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results

Monday, January 27, 2020 - 9:00pm

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2019 on Thursday, February 6, 2020, before the U.S. financial markets open.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2019 on Thursday, February 6, 2020, before the U.S. financial markets open.
  • Management will provide an update on the Company and discuss fourth quarter and year-end 2019 results as well as expectations for the future via conference call on Thursday, February 6, 2020 at 8:30 am ET.
  • To access the call, please dial 800-239-9838 (domestic) or +1-323-794-2551 (international) five minutes prior to the start time and refer to conference ID 6976021.
  • A replay of the call will be available beginning at 11:30 am ET on the day of the call.